Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation

Persistent Atrial Fibrillation Clinical Trial

— CLAAAF  

Official title:

Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01144858
• Other study ID #: past-1001-ryth
• Status: Terminated
• Phase: N/A
• First received: June 15, 2010
• Last updated: June 15, 2010
• Start date: January 2009
• Est. completion date: December 2009

Study information

• Verified date: October 2008
• Source: Clinique Pasteur
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Direction Générale de la Santé
• Study type: Observational

Clinical Trial Summary

The purpose of this study was to determine whether left atrial appendage flow velocity, as determined using trans esophageal echocardiography (TEE), predicts the outcome after catheter ablation of persistent Atrial fibrillation( pAF).

Description:

40 PAF patients underwent 3D mapping and ablation. A stepwise approach including circumferential pulmonary vein (PV) isolation, continuous complex-fractionated electrogram (CFE) ablation and linear ablation was performed by the same operator. The procedural end point was termination of persistent AF by catheter ablation, either by conversion directly to sinus rhythm or to atrial tachycardia. Left atrial appendage (LAA) peak flow velocities were measured with transesophageal echography and averaged within each RR interval of 10 consecutive cardiac cycles.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: December 2009
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• First-time radiofrequency catheter ablation for pAF. pAF was defined as continuous AF lasting longer than 1 month, resistant to either electrical or pharmacological cardioversion.

• Informed consent

Exclusion Criteria:

• Severe valvular disease requiring surgery

• Valvular prosthesis

• Known severe coronary artery disease

• Atrial and/or ventricular thrombosis

• New York Heart Association functional class III to IV

• Cerebrovascular disease

• Pulmonary embolism

• Latent or manifest hyperthyroidism

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atrial Fibrillation
• Catheter Ablation
• Persistent Atrial Fibrillation

Intervention

Other:
• a complete transesophageal echocardiography
All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles

Locations

Country	Name	City	State
France	Clinique Pasteur	Toulouse	43-45 avenue de Lombez

Sponsors (1)

Lead Sponsor	Collaborator
Clinique Pasteur

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	termination of persistent AF by catheter ablation			Yes
Secondary	Recurrences of AF were therefore determined from holter monitoring at 3 and 6 months or 12 leads ECG in care of symptomatic palpitation with clinical interview.			Yes